Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
Phyllis Foxworth discusses how clinicians and patients can work together to more closely align their goals and outcomes when treating mood disorders, and explores realistic expectations for treatment and tips for family and friends of...
Phyllis Foxworth discusses how clinicians and patients can work together to more closely align their goals and outcomes when treating mood disorders, and explores realistic expectations for treatment and tips for family and friends of...
Phyllis Foxworth addresses how the COVID-19 pandemic has exacerbated feelings of isolation in patients with bipolar 1 disorder (BD-I) and tools for clinicians who are treating these patients.
Phyllis Foxworth addresses how the COVID-19 pandemic has exacerbated feelings of isolation in patients with bipolar 1 disorder (BD-I) and tools for clinicians who are treating these patients.
Craig Chepke, MD, FAPA, shares his key insights and takeaways regarding the burden on people living with bipolar I disorder, especially as it relates to the importance of person-centered care.
Craig Chepke, MD, FAPA, shares his key insights and takeaways regarding the burden on people living with bipolar I disorder, especially as it relates to the importance of person-centered care.
Craig Chepke, MD, FAPA, discusses the impact of COVID-19 and the burden on people living with bipolar I disorder, specifically the important topics of isolation, medication trial and error, and stigma.
Craig Chepke, MD, FAPA, discusses the impact of COVID-19 and the burden on people living with bipolar I disorder, specifically the important topics of isolation, medication trial and error, and stigma.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the utility and limitations of pharmacogenetics in the treatment of bipolar disorders.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the utility and limitations of pharmacogenetics in the treatment of bipolar disorders.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the concept of polarity-proneness and why clinicians should assess it when treating patients with bipolar disorder.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains the concept of polarity-proneness and why clinicians should assess it when treating patients with bipolar disorder.
Jessica Whelan, DNP, APRN, FPMHNP-BC reviews the many factors that come in to play when she is developing a treatment plan for her patients with bipolar disorder.
Jessica Whelan, DNP, APRN, FPMHNP-BC reviews the many factors that come in to play when she is developing a treatment plan for her patients with bipolar disorder.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains some key distinctions between bipolar I disorder and bipolar II disorder and treatment implications of the differences.
Bipolar Disorders Section Editor Joseph F. Goldberg, MD, explains some key distinctions between bipolar I disorder and bipolar II disorder and treatment implications of the differences.
Jessica Whelan, DNP, APRN, FPMHNP-BC discusses the value of understanding the neurobiology behind bipolar disorder and how she explains it to her patients.
Jessica Whelan, DNP, APRN, FPMHNP-BC discusses the value of understanding the neurobiology behind bipolar disorder and how she explains it to her patients.
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder.
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
Methylphenidate improved driving performance in adults by reducing lane weaving and speed variation, according to results from a recent randomized controlled trial published in the Journal of Psychopharmacology.
Methylphenidate improved driving performance in adults by reducing lane weaving and speed variation, according to results from a recent randomized controlled trial published in the Journal of Psychopharmacology.
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
Elevated translocator protein (TSPO) binding, a marker of neuroinflammatory processes, was associated with more pronounced daily suicidal ideation and negative affect during real-world stress in patients with major depressive disorder (MDD).
Elevated translocator protein (TSPO) binding, a marker of neuroinflammatory processes, was associated with more pronounced daily suicidal ideation and negative affect during real-world stress in patients with major depressive disorder (MDD).
A recent report from the National Center for Health Statistics found many decreases in drug overdose deaths between 2022 and 2023, though certain subsections remained stable or increased year over year, according to the CDC and the National...
A recent report from the National Center for Health Statistics found many decreases in drug overdose deaths between 2022 and 2023, though certain subsections remained stable or increased year over year, according to the CDC and the National...
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
Combining brexpiprazole and sertraline in treatment of post-traumatic stress disorder (PTSD) significantly improved PTSD symptoms when compared with sertraline and placebo treatment, according to results from a randomized clinical trial...
Combining brexpiprazole and sertraline in treatment of post-traumatic stress disorder (PTSD) significantly improved PTSD symptoms when compared with sertraline and placebo treatment, according to results from a randomized clinical trial...
Intermittent explosive disorder (IED) was found to have many comorbidities, including substance use disorder, neurodegenerative diseases, sleep disorders, and many somatic diseases, according to a recent cohort study published in JAMA...
Intermittent explosive disorder (IED) was found to have many comorbidities, including substance use disorder, neurodegenerative diseases, sleep disorders, and many somatic diseases, according to a recent cohort study published in JAMA...
Symptoms of attention-deficit/hyperactivity disorder (ADHD) were associated with a lower academic performance in college students, especially those with inattention symptoms, according to a recent systematic review published in the Journal of...
Symptoms of attention-deficit/hyperactivity disorder (ADHD) were associated with a lower academic performance in college students, especially those with inattention symptoms, according to a recent systematic review published in the Journal of...
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
Although the diagnostic criteria for the two conditions seem distinctive at first glance, there is a significant degree of variability of symptom presentation.
Although the diagnostic criteria for the two conditions seem distinctive at first glance, there is a significant degree of variability of symptom presentation.
Help me to let go and Live, to bloom in resonance with the rest of our passionate universe. To see my own life as something sacred and not just a death sentence to serve until it is finally over.
Help me to let go and Live, to bloom in resonance with the rest of our passionate universe. To see my own life as something sacred and not just a death sentence to serve until it is finally over.
To truly recover, the questions surrounding survival become more basic, more fundamental, and less focused on a particular disorder. They become more about life.
To truly recover, the questions surrounding survival become more basic, more fundamental, and less focused on a particular disorder. They become more about life.
The foundational piece in each part of my journey today has been my relationship with my treatment team. When treating a client, it is important to remember that you may be the only close relationship they have or can trust.
The foundational piece in each part of my journey today has been my relationship with my treatment team. When treating a client, it is important to remember that you may be the only close relationship they have or can trust.
Years after my time in the VA hospital, I had been asked to present back at the hospital in which I was once a patient. In the back row was an MD who seemed to be on the brink of tears. This was the doctor I thought was trying to kill me when...
Years after my time in the VA hospital, I had been asked to present back at the hospital in which I was once a patient. In the back row was an MD who seemed to be on the brink of tears. This was the doctor I thought was trying to kill me when...
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Rakesh Amin, MD, discusses the importance of partnering with patients and caregivers to set treatment goals and the importance of introducing long-acting injectables earlier in the treatment of schizophrenia.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD, discusses the need for a clinical refocusing that includes broad access to psychosocial solutions and ensuring socially informed clinicians can help underserved communities.
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Ed Jones, PhD: "We miss this psychosocial aspect of care today...What is missing? We need psychotherapists based in primary care, often focused on mundane issues rather than the complexities of diagnosis or treatment."
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
Andrew Penn, NP, explains mentoring, how to find one as an NP, and what to do when you have found a possible mentor. He gives practical advice, questions to ask, and avenues to find the right fit.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
In this blog, Julie Bailey, LCPC, shares her insights on providing a safe space for patients to discuss these social anxieties, as well as tips to share with patients about slowly reintegrating into life after COVID-19.
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
Background: This study evaluated the dose-response relationship of efficacy, safety, and tolerability for single-dose MM120 (lysergide D-tartrate) vs placebo in participants with generali...
Risperidone, an atypical antipsychotic, is known to be the most likely of its class of medication to cause hyperprolactinemia. We present a case of a 33 year old female with no known psyc...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
It is...
How to Use
Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
It is...
How to Use
The Bipolar Spectrum Diagnostic Scale (BSDS) is a descriptive story that captures subtle features of bipolar illness. It does not provide a “yes” or “no” answer to whether or not a patient has bipolar disorder – it addresses the...
How to Use
The Bipolar Spectrum Diagnostic Scale (BSDS) is a descriptive story that captures subtle features of bipolar illness. It does not provide a “yes” or “no” answer to whether or not a patient has bipolar disorder – it addresses the...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for Medication Adherence Rating Scale (MARS) - page 7
The total score ranges from 0-10 with a higher score indicating better adherence
Strengths
Self-report...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
Click here for website for SDS
How to Use
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life.
How to Score
Total score 0-30 (0 unimpaired, 30 highly...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The Brief Psychiatric Rating Scale (BPRS) is a comprehensive 24-item symptom scale.
The BPRS is used as part of a clinical interview in which the clinician makes...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI is a widely used psychiatric structured diagnostic interview instrument.
To keep the interview brief, tell the patient the interview is structured and requires only “yes” or “no” answers.
The MINI...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The MINI Screen is a subset (2 pages) of the complete MINI and acts as a tool to refer healthcare providers to the complete MINI.
Click here for the website for the MINI Screen
How to...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
The Patient Health Questionnaire (PHQ-9) is a brief, 9-item self-report screening tool that may help identify symptoms that could relate to depression. The PHQ-9 was developed for use in primary care...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
Five items rated on 6-point Likert scale
Subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
How to Use
The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient.
The MDQ consists of 15 questions and takes about 5 minutes to complete. The first 13 questions about...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Click here for a PDF of the HAM-A
Developed in 1959 by Dr. M. Hamilton, the scale has proven useful not only in following individual patients but also in...
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.